Xiaofeng Wu

机构：Nanjing Normal University, Pfizer (United States) · ORCID：0000-0002-8961-2163

发表论文 150 篇 · 总被引 2576 次 · h-index 27

代表论文

• Lactate-mediated lactylation in human health and diseases: Progress and remaining challenges (2024 · Journal of Advanced Research · 被引 42)
• Artificial intelligence for the noninvasive diagnosis of clinically significant portal hypertension (2025 · EngMedicine · 被引 31)
• Phosphorus recovery and reuse: Innovating with biochar in the circular economy (2025 · The Science of The Total Environment · 被引 14)
• AI-assisted SERS imaging method for label-free and rapid discrimination of clinical lymphoma (2025 · Journal of Nanobiotechnology · 被引 11)
• METTL3 methylated KIF15 promotes nasopharyngeal carcinoma progression and radiation resistance by blocking ATG7-mediated autophagy through the activation of STAT3 pathway (2024 · Translational Oncology · 被引 11)
• Modulation of Gut Microbiota and Glucose Homeostasis through High-Fiber Dietary Intervention in Type 2 Diabetes Management (2024 · Journal of improved oil and gas recovery technology. · 被引 10)